4502 Takeda Pharmaceutical
- 4217.0
- +25.0+0.60%
Takeda Pharmaceutical News
Takeda Pharmaceutical: 2024 Annual Integrated Report
Takeda Pharmaceutical: 2024 Integrated Report
Takeda Pharmaceutical: Annual Securities Report for the period from April 1, 2023 to March 31, 2024 (Fiscal year 147)
Takeda Pharmaceutical: Takeda Pharmaceutical announces new board of directors appointment.
Takeda Pharmaceutical: About the decision regarding the allocation of directors' responsibilities.
Takeda Pharmaceutical: Takeda Pharmaceutical announced the Phase III topline results of Soticlestat (TAK-935) for patients with Dravet syndrome and Lennox-Gastaut syndrome.
Takeda Pharmaceutical: Topline results of the phase 3 clinical trial of Soticlestat (TAK-935) targeting patients with Dravet syndrome and Lennox-Gastaut syndrome.
Takeda Pharmaceutical: Issuance of new shares and disposal of treasury shares based on a long-term incentive plan for employees of conglomerates outside Japan.
Takeda Pharmaceutical: Announcements of individual stocks regarding the pricing of Japan's diversified bonds.
Takeda Pharmaceutical: Announcements of individual stocks regarding the determination of the conditions for yen-denominated hybrid corporate bonds.
Takeda Pharmaceutical: The latest presentation of Phase 2b data for TAK-861 SLEEP 2024 showed clinically significant effects of an oral orexin agonist in NT1.
Takeda Pharmaceutical: Regarding the announcement of the clinical phase 2b trial data of TAK-861, which demonstrates statistically significant and clinically meaningful improvement, at SLEEP 2024.
Takeda Pharmaceutical: Notice regarding withdrawal of shelf registration forms and submission of new shelf registration forms in Japan
Takeda Pharmaceutical: Independent Officer Notification Form
Takeda Pharmaceutical: (Correction) Partial correction to the summary of financial statements for the fiscal year ended 2024/3/31 (IFRS, consolidated)
Takeda Pharmaceutical: Continuation of the stock compensation system for our directors and the share grant system for our domestic executives in 2024
Takeda Pharmaceutical: Japan's stock compensation system for directors and share grant system for company managers will continue in 2024
Takeda Pharmaceutical: On the passing of director Olivier Bohuon
Takeda Pharmaceutical: Takeda Pharmaceutical Co., Ltd. sadly announces the passing of Olivier Bohuon director
Takeda Pharmaceutical: Takeda Announces Company-wide Program to Support Growth and Achieve Core Operating Margin Improvement
Analysis
Price Target
No Data
